The narrow possibilities for coverage of Alzheimer’s disease therapies under the US Centers for Medicare and Medicaid Services’ current coverage decision has eliminated the need to push for a quick accelerated approval of its Alzheimer’s candidate donanemab, Eli Lilly and Company execs told the firm’s fourth quarter and full year 2021 earnings call on 3 February. Instead, Lilly will wait for Phase III data that could be more convincing for payers, practitioners and regulators.
Lilly still intends to file for accelerated approval of its amyloid-clearing antibody donanemab in Alzheimer’s disease but has backed away...
